Hilltop Holdings Inc. Invests $2.94 Million in Kenvue Inc. (NYSE:KVUE)

Hilltop Holdings Inc. bought a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, HoldingsChannel reports. The firm bought 136,562 shares of the company’s stock, valued at approximately $2,940,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clearstead Advisors LLC bought a new stake in Kenvue during the third quarter worth $25,000. Planned Solutions Inc. bought a new position in shares of Kenvue in the 4th quarter valued at about $27,000. EverSource Wealth Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter worth about $28,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at about $28,000. Finally, CVA Family Office LLC acquired a new stake in Kenvue in the 4th quarter valued at about $32,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock traded down $0.09 during midday trading on Friday, hitting $19.35. The company’s stock had a trading volume of 24,363,713 shares, compared to its average volume of 27,176,828. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The company has a market cap of $37.05 billion and a price-to-earnings ratio of 24.81. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $26.74. The company has a 50-day moving average price of $19.99 and a two-hundred day moving average price of $20.21.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm’s revenue was down 24.9% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.13%. Kenvue’s payout ratio is 102.56%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent analyst reports. Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. William Blair initiated coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, HSBC increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.